bioTheranostics & Syapse Collaborate To Integrate Genomics-Based Molecular Diagnostics For Cancer Into The Syapse Precision Medicine Platform

Breast Cancer Index & CancerTYPE ID Tests Provide Patient-Specific Information to Aid in Treatment Decisions with the Goal of Improving Outcomes

SAN DIEGO & PALO ALTO, Calif.--(BUSINESS WIRE)--Biotheranostics, Inc., a pioneer in molecular diagnostics for cancer, and Syapse, the leader in precision medicine software, announce plans to integrate data from Biotheranostics’ CancerTYPE ID^® and Breast Cancer Index^SM genomic tests into the Syapse Precision Medicine Platform. The software-based service is part of Syapse’s Global Partner Program that aims to leverage strong collaborators toward an integrative approach to precision medicine.

“We are excited to work with Syapse to make our Breast Cancer Index and CancerTYPE ID clinical testing services available to more health systems through the Syapse Precision Medicine Platform”

The collaboration allows for seamless integration of patient-specific results from Biotheranostics’ proprietary biomarkers that provide molecular profiles for patients with early stage breast cancer and metastatic cancer into the Syapse Precision Medicine Platform. The platform is used by health systems and cancer care networks, providing decision support to clinicians in the care of cancer patients and enabling health systems to make precision medicine a routine part of cancer care. Syapse is deployed at some of the largest and most prominent healthcare institutions in the nation.

Biotheranostics’ Breast Cancer Index helps oncologists make difficult decisions about extended endocrine therapy for ER+, early stage breast cancer patients based on its unique ability to predict the risk of late disease recurrence and identify which patients are likely to benefit from continuing adjuvant endocrine therapy beyond five years. Its CancerTYPE ID is a rigorously validated gene expression-based test for metastatic patients with diagnostic ambiguity. By providing a molecular classification of tumor type, results are used in conjunction with standard clinical and pathological assessment, which may help physicians determine optimal targeted treatment regimens with the goal of improving patient outcomes.

“We are excited to work with Syapse to make our Breast Cancer Index and CancerTYPE ID clinical testing services available to more health systems through the Syapse Precision Medicine Platform,” said Nicolas Barthelemy, President and Chief Executive Officer of Biotheranostics. “Precision medicine promises to transform healthcare over the next several decades. We are committed to helping physicians find the most effective treatment for each cancer patient based on his or her specific molecular profile. Integrating data from our molecular tests with the Syapse platform will better help physicians harness individualized patient information to extend lives and reduce costs.”

About Syapse

Syapse drives healthcare transformation through precision medicine, enabling provider systems to improve clinical outcomes, streamline operations, and shift to new payment models. Syapse Precision Medicine Platform is a comprehensive software suite used by leading health systems to support the clinical implementation of precision medicine in oncology and other service lines. This category-defining platform enables clinical and genomic data integration, decision support, care coordination, and quality improvement at point of care. Headquartered in Palo Alto, California, with offices in Philadelphia, Pennsylvania, Syapse is backed by Ascension Ventures, Safeguard Scientifics (NYSE:SFE), and Social Capital. For more information, visit syapse.com.

About Biotheranostics

Biotheranostics, Inc., is a leader in helping physicians improve the care of cancer patients, offering a suite of proprietary genomics-based molecular diagnostics that allow treatment to be tailored to individual patients. The company’s Breast Cancer Index^SM and CancerTYPE ID^® tests address a variety of unmet medical needs in the management of cancer patients, and extensive clinical studies have confirmed the accuracy, clinical validity, clinical utility, and cost-effectiveness of the tests. Biotheranostics operates a CLIA-certified, CAP-accredited diagnostic laboratory in San Diego. Learn more at biotheranostics.com.